【摘要】 目的:观察马来酸曲美布汀治疗功能性消化不良(FD)的疗效及安全性。方法:62例FD患者随机分为治疗组和对照组,治疗组用马来酸曲美布汀100 mg,每日3次,对照组用多潘立酮10mg,每日3次,疗程均为4周。记录治疗前后症状并进行评分。结果:治疗组治疗前、后症状总积分分别为11.82±2.03和3.24±2.67,对照组治疗前、后症状总积分分别为11.39±3.92和3.46±2.91,均有显著差异(P<0.01);疗程结束时FD患者早饱、上腹胀、上腹痛、嗳气、食欲不振及烧心等症状均可明显改善,治疗组、对照组症状总改善率分别为(72.69±26.75)％和(68.85±23.94)％,与治疗前相比,差异有显著性(P<0.05);但两组治疗前后的症状总积分及症状总改善率均无显著性差异(P>0.05)。两组治疗过程中均未发现不良反应。结论:马来酸曲美布汀是治疗FD安全、有效的新一代胃肠动力药物。更多还原

【Abstract】 Objective:To observe the effect and safety of Trimebutine malcate on functional dyspepsia treatment. Methods: 62 patients with functional dyspepsia were divided into two groups randomly. The treatment group was treated by Trimebutine malcate (100 mg, T.i.d). The control group was treated by Domperidone (100 mg, T.i.d). Both groups treating period was 4 weeks. Writing down the symptoms both before and after the treatment, and giving rating to the symptoms. Results:The overall rating of the treatment group: before treatment:19.82±2.03; after treatment:3.24±2.67. The difference was obvious(P< 0.01). The overall rating of the control group: before treatment: 11.39±3.92; after treatment:3.46±2.91. The difference was also obvious (P<0.01). Patients in both groups got better in the following symptoms: early satiety, abdominal distention, abdominal pain, heartburn, anorexia, belching and so on(72.69±26.75)% of patients in the treatment got better (68.85±23.94)% of patients in the control group got better. In both groups, the difference between before treatment and after treatment was great (P<0.05). The overall rating and the symptoms improving percentage between the two teams were not obvious (P>0.05). Bad effect did not exist in both teams after treatments. Conclusions: Trimebutine malcate is a safe, effective new generation drug for functional dyspepsia.更多还原